Comparing 2 hypotheses side-by-side
Prohibitin-2 serves as a convergent mitochondrial platform where tau, α-synuclein, and TDP-43 interact and undergo conformational templating. Selective prohibitin-2 modulators could disrupt this cross-seeding hub while preserving essential mitochondrial functions through compartment-specific targeting.
Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | Prohibitin-2 Mitochondrial Cro | Transglutaminase-2 Cross-Linki |
|---|---|---|
| Mechanistic | 0.550 | 0.750 |
| Evidence | 0.450 | 0.600 |
| Novelty | 0.750 | 0.700 |
| Feasibility | 0.300 | 0.800 |
| Impact | 0.500 | 0.700 |
| Druggability | 0.250 | 0.850 |
| Safety | 0.300 | 0.650 |
| Competition | 0.800 | 0.750 |
| Data | 0.400 | 0.700 |
| Reproducible | 0.350 | 0.750 |
| KG Connect | 0.672 | 0.742 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["PHB2 on Mitochondrial Inner Membrane"] --> B["Scaffolding/Structural Role"]
B --> C["Cristae Organization"]
B --> D["Mitophagy Receptor Function"]
E["Tau"] --> F["Binds PHB2 on Mito Surface"]
G["alpha-Synuclein"] --> F
H["TDP-43"] --> F
F --> I["PHB2 as Convergent Cross-Seeding Hub"]
I --> J["Conformational Templating"]
J --> K["Heterologous Protein Aggregation"]
K --> L["Multi-Protein Toxic Complexes"]
L --> M["Mitochondrial Membrane Disruption"]
M --> N["Bioenergetic Collapse"]
N --> O["Neurodegeneration"]
P["PHB2 Modulator Therapy"] --> Q["Disrupt PHB2-Aggregate Interaction"]
Q --> R["Block Cross-Seeding Platform"]
R --> S["Prevent Multi-Protein Aggregation"]
Q --> T["Preserve PHB2 Scaffolding Function"]
T --> U["Maintained Cristae Integrity"]
S --> V["Neuroprotection"]
U --> V
style A fill:#264653,stroke:#ffd54f,color:#e0e0e0
style I fill:#3a1a1a,stroke:#ef9a9a,color:#e0e0e0
style P fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
style V fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0
graph TD
A["""Neuroinflammation
& Calcium Dysregulation"""] -->|"Ca2+ Influx"| B["TG2 Activation
(Transglutaminase-2)"]
B -->|"Isopeptide Bond
Formation"| C["Tau Cross-Linking
& Aggregation"]
B -->|"Protein Cross-Linking"| D["Abeta Oligomer
Stabilization"]
B -->|"ECM Cross-Linking"| E["BBB Disruption
& Matrix Stiffening"]
B -->|"NF-kappaB Activation"| F["Pro-inflammatory
Cytokine Cascade"]
C --> G["Neurofibrillary
Tangle Formation"]
D --> H["Amyloid Plaque
Stabilization"]
E --> I["Peripheral Immune
Cell Infiltration"]
F --> J["Chronic
Neuroinflammation"]
G --> K["Neuronal Death
& Cognitive Decline"]
H --> K
I --> J
J --> K
L["""TG2 Inhibitor
Therapy"""] -->|"Selective Active-Site
Blockade"| M["TG2 Cross-Linking
Inhibition"]
M -->|"Reduced Tau
Cross-Linking"| N["Prevented Tangle
Formation"]
M -->|"Reduced Abeta
Stabilization"| O["Enhanced Abeta
Clearance"]
M -->|"Preserved BBB
Integrity"| P["Reduced Immune
Infiltration"]
M -->|"Suppressed NF-kappaB"| Q["Reduced
Neuroinflammation"]
N --> R["Neuroprotection &
Cognitive Preservation"]
O --> R
P --> R
Q --> R
style A fill:#ff8a80,stroke:#d32f2f,color:#000
style L fill:#4fc3f7,stroke:#2196f3,color:#000
style R fill:#81c784,stroke:#4caf50,color:#000
style K fill:#ffab91,stroke:#e64a19,color:#000